Redifferentiation Therapy with 13-cis Retinoic Acids in Radioiodine-Resistant Thyroid Cancer

Endocrine Journal

Tae Yong KIM²  Eui Young KIM²  Jin-Sook RYU³  Young Kee SHONG²  Won Bae KIM²  Won Gu KIM²  Suck Joon HONG¹ 

[1] Department of Surgery, Asan Medical Center, University of Ulsan College of Medicine;Department of Endocrinology & Metabolism, University of Ulsan College of Medicine;Department of Nuclear medicine, University of Ulsan College of Medicine

关键词: Thyroid cancer;    13-;    cis Retinoic acid;    Radioiodine therapy;    Redifferenciation;    Thyrogolobulin;   

DOI  :  10.1507/endocrj.K08E-254

学科分类：内分泌与代谢学

来源: Japan Endocrine Society

【 摘 要 】

References(27)Cited-By(20)Radioiodine (I-131) therapy is of proven efficacy for treatment of differentiated thyroid carcinoma (DTC). However, loss of differentiation in recurrent or metastatic DTC which decrease I-131 uptake may decrease the efficacy of I-131 therapy. Therefore, strategies to improve I-131 uptake are mandatory. This study is an open label clinical study to evaluate the effectiveness of 13-cis retinoic acid (13-cis RA) for improving I-131 uptake in recurrent or metastatic of DTC with defective I-131 uptake. Eleven patients (Age 27-66 years, M : F=4 : 7) were given 13-cis RA (1.5 mg/kg daily for 5 weeks), followed by 200 mCi (7.4 GBq) I-131 treatment. The differences of serum thyroglobulin (Tg) level and I-131 uptake on the post-treatment whole body scan (RxWBS) were compared before and after 13-cis RA therapy. Six out of 11 patients showed significantly increased (above 50%) Tg levels just after RA therapy. However, Tg levels a year after I-131 therapy were increased, stable and decreased in 7, 2 and 1 patients, respectively. Iodine uptake on RxWBS showed marginal improvement in only 2 patients and their Tg levels after one year follow-up increased. Most frequent adverse events were dry skin and lips. 13-cis RA partially restores I-131 uptake in few patients with recurrent or metastatic DTC. The use of 13-cis RA in current protocol has only limited usefulness and is not routinely recommended as currently used protocol.

【 授权许可】

Unknown